F Rüfer1, A Frimpong-Boateng, A Bunse, J Roider. 1. Klinik für Ophthalmologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Hegewischstrasse 2, 24105, Kiel, Germany. fruefer@ophthalmol.uni-kiel.de
Abstract
BACKGROUND: Pars plana vitrectomy with internal limiting membrane (ILM) peeling is the best known therapy for idiopathic macular holes. Indocyanine green (ICG) is useful for staining the ILM, although there is a dose related toxic effect on the inner retinal layers. We compared outcome results with and without the use of ICG. METHOD: Data from 61 patients with idiopathic macular holes, who underwent macular hole surgery were analyzed retrospectively. ICG was used on 36 eyes while for 25 eyes it was not used. After calculating logMAR, differences in visual acuity between both groups were analyzed for significance using the Mann-Whitney-U-Test. RESULTS: The logMAR for the entire group was 0.71+/-0.30 (20/100) preoperatively, after 1 month 0.71+/-0.36 (20/100), after 3 months 0.57+/-0.26 (20/80), after 6 months 0.54+/-0.38 (20/66) and after 12 months 0.36+/-0.32 (20/50). There were no significant differences between groups. CONCLUSION: There seem to be no significant differences in the development of visual acuity and the occlusion rate between patients treated with or without the use of ICG.
BACKGROUND: Pars plana vitrectomy with internal limiting membrane (ILM) peeling is the best known therapy for idiopathic macular holes. Indocyanine green (ICG) is useful for staining the ILM, although there is a dose related toxic effect on the inner retinal layers. We compared outcome results with and without the use of ICG. METHOD: Data from 61 patients with idiopathic macular holes, who underwent macular hole surgery were analyzed retrospectively. ICG was used on 36 eyes while for 25 eyes it was not used. After calculating logMAR, differences in visual acuity between both groups were analyzed for significance using the Mann-Whitney-U-Test. RESULTS: The logMAR for the entire group was 0.71+/-0.30 (20/100) preoperatively, after 1 month 0.71+/-0.36 (20/100), after 3 months 0.57+/-0.26 (20/80), after 6 months 0.54+/-0.38 (20/66) and after 12 months 0.36+/-0.32 (20/50). There were no significant differences between groups. CONCLUSION: There seem to be no significant differences in the development of visual acuity and the occlusion rate between patients treated with or without the use of ICG.
Authors: Nicholas E Engelbrecht; Jiong Freeman; Paul Sternberg; Thomas M Aaberg; Thomas M Aaberg; Daniel F Martin; Brian D Sippy Journal: Am J Ophthalmol Date: 2002-01 Impact factor: 5.258
Authors: Ingrid U Scott; Alexei L Moraczewski; William E Smiddy; Harry W Flynn; William J Feuer Journal: Am J Ophthalmol Date: 2003-05 Impact factor: 5.258
Authors: Antonio P Ciardella; William Schiff; Gaetano Barile; Orit Vidne; Janet Sparrow; Kevin Langton; Stanley Chang Journal: Am J Ophthalmol Date: 2003-07 Impact factor: 5.258
Authors: Marcin P Czajka; Brooks W McCuen; Thomas J Cummings; Hoang Nguyen; Sandra Stinnett; Fulton Wong Journal: Retina Date: 2004-04 Impact factor: 4.256